Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System
• Men and women with a diagnosis of metastatic invasive breast cancer with a ECOG PS≤2
• Participant is ≥ 18 years old.
• Hair present at baseline.
• One of the following full dose chemotherapy regimens must be planned for at least 4 cycles:
‣ Sacituzumab govitecan (IMMU-132) 10 mg/kg administered intravenously on days 1 and 8 of each 21-day cycle
⁃ Trastuzumab deruxtecan 5.4 mg/kg administered intravenously once every 3 weeks
⁃ Eribulin 1.4 mg/m2 administered intravenously on days 1 and 8 of each 21-day cycle
• The Paxman Scalp Cooling System must be initiated with the first dose of therapy in participants that elect to participate in the scalp cooling group.